Cell cryopreservation market projected to hit $90.92 billion by 2035

Market Research Future says the global cell cryopreservation market will grow from $17.89 billion in 2026 to $90.92 billion by 2035, driven by cell and gene therapy scale-up, biobank expansion and automation in cryogenic storage. The outlook points to rising demand for validated storage, media and equipment across biopharma, research and fertility care.

Why it matters: - Cell cryopreservation is becoming core infrastructure for cell and gene therapy manufacturing, national biobanks and fertility services. - The market’s forecast jump from $17.89 billion in 2026 to $90.92 billion by 2035 signals sustained demand for storage systems, media and automation. - The projected 19.8% CAGR reflects a shift from niche lab use to recurring commercial and public-sector demand.

What happened: - Market Research Future projected the global cell cryopreservation market to reach $90.92 billion by 2035, up from $17.89 billion in 2026. - The firm estimated the market at $14.93 billion in 2025. - The forecast was released June 25, 2026. - The company linked the growth outlook to scale-up in cell and gene therapy pipelines and government biobank expansion. - The report also pointed to a shift toward automated, closed-system cryogenic storage and vitrification-based freezing. - Request a free sample

The details: - More than 1,900 active clinical trials were in the global cell and gene therapy pipeline by mid-2025. - The FDA approved more than 20 novel cell and gene therapies between 2022 and 2024. - Validated cryogenic storage is needed at the apheresis center, manufacturing suite and point of care for commercial cell and gene therapy products. - BioLife Solutions’ CryoStor line and Thermo Fisher’s Gibco media portfolio have become standard offerings in the market. - Combined R&D investment in those portfolios has exceeded $420 million since 2022. - China’s National Biobank Network planned more than $850 million in investment from 2024 to 2028 for 15 regional tissue repositories. - UK Biobank holds more than 1.1 million biological samples. - More than 300,000 people have enrolled in the All of Us Research Program in the U.S. - India’s National Biopharma Mission targets 20 new biorepositories by 2028. - Brazil’s FAPESP program is funding five regional tissue banks. - Vitrification-based stem cell freezing has shown post-thaw viability above 90%. - Machine-learning tools are being used to optimize freeze-thaw protocols in real time. - Read the detailed insights

Between the lines: - The forecast suggests cryopreservation is moving from a back-end laboratory function to a regulated, revenue-generating part of the life-sciences supply chain. - GMP and regulatory requirements are pushing buyers toward chemically defined, xeno-free media and automated equipment. - The premium tier matters because it can carry margins 30% to 40% above research-grade alternatives. - High equipment costs, which can run from $45,000 to $120,000 per automated freezer, may slow adoption among smaller research institutes and IVF clinics. - Leasing and equipment-as-a-service models are emerging to close that gap. - The market remains concentrated, with the top five players holding an estimated 45% to 52% of global revenue. - Thermo Fisher Scientific held about 12% to 15% of global revenue and expanded Gibco CTS cryopreservation media manufacturing in Grand Island, New York, in June 2024, adding 40% capacity. - Merck KGaA held about 8% to 11% of global revenue and bought a controlling stake in a Swiss cryobiology startup in March 2024 to expand DMSO-free vitrification media. - BioLife Solutions held about 7% to 10% of global revenue and has become a key CGT cold-chain integrator.

What’s next: - Asia-Pacific is expected to remain the fastest-growing region at a projected 22.4% CAGR from 2026 to 2035. - North America is expected to stay the largest market, while Europe remains the second largest. - Digital biobank platforms, electronic sample management and AI-driven cryopreservation are expected to deepen market adoption through the early 2030s. - The report says those tools could widen cryogenic storage use beyond centralized biobanks to clinical trial sites and fertility clinics. - More related research, stem cell therapy, regenerative medicine, biobanking, cell culture media, cryogenic equipment, gene therapy, personalized medicine